Pfizer Inc. has discovered substituted pyridine compounds acting as sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors and thus described as potentially useful for the treatment of diabetes, chronic kidney disease, nonalcoholic fatty liver disease (NAFLD; MASLD), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism-spectrum disorders, among others.
The Korea Institute of Science and Technology (KIST) and Neocannbio Co. Ltd. have jointly identified compounds acting as nitric oxide (NO) production inhibitors with potential for the treatment of inflammatory bowel disease (IBD).
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors for use in the treatment of cancer.
CHA University has identified chalcone derivatives acting as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitors potentially useful for the treatment of Alzheimer’s disease.
Rongchang Pharmaceutical (Zibo) Co. Ltd. has synthesized nitrogen-containing fused ring compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of obesity and diabetes.
Dice Alpha Inc. has disclosed interleukin-17A (IL-17A) inhibitors designed for use in the treatment of psoriasis, rheumatoid arthritis, multiple sclerosis and more.
Therapex Co. Ltd. has identified pyrimidine derivatives acting as EGFR (HER1; erbB1) mutant inhibitors described as potentially useful for the treatment of cancer.
RSS